Clinical trial
Oxaliplatin in Esophagus Cancer (Advanced) 1st Line
NCT00259402 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00259402 |
|---|---|
| Title | Oxaliplatin in Esophagus Cancer (Advanced) 1st Line |
| Official title | Phase II Open-label Single Arm Study of Oxaliplatin Combined With Cisplatin and 5FU in Advanced Esophagus Cancer Patients |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Esophageal Neoplasms |
| Intervention type | Drug |
| Interventions | Oxaliplatin + cisplatin + 5-Fluorouracil (5-FU) |
| Enrollment | 41 |
| Start date | Feb 1, 2000 |
| Primary completion | Oct 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Nov 29, 2005 |
| Last update posted | Dec 7, 2009 |
| Countries | Spain |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: